Adjuvant Therapy for Thymic Carcinoma--A Decade of Experience in a Taiwan National Teaching Hospital

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2016 Jan 13

PMID 26757052

Citations 4

Authors

Yen-Han Tseng

Yi-Hsuan Lin

Yen-Chiang Tseng

Yu-Chin Lee

Yu-Chung Wu

Wen-Hu Hsu

Sang-Hue Yen

Jacqueline Whang-Peng

Yuh-Min Chen

Affiliations

Soon will be listed here.

Abstract

Background: Thymic carcinomas are rare tumors for which surgical resection is the first treatment of choice. The role of adjuvant treatment after surgery is unknown because of limited available data. The present study evaluated the efficacy of post-surgery adjuvant chemotherapy or radiotherapy in patients with thymic carcinoma.

Methods: To evaluate the role of adjuvant therapy in patients with thymic carcinoma, we retrospectively reviewed the records of patients with thymic carcinoma who were diagnosed and treated between 2004 and 2014.

Results: Among 78 patients with thymic carcinoma, 30 patients received surgical resection. Progression-free survival (PFS) and overall survival (OS) were significantly longer among these patients than among patients who received other treatments (PFS: 88.4 months vs 9.1 months, p<0.001; OS: 134.9 months vs 60.9 months; p = 0.003). Patients with stage III thymic carcinoma who received surgery had a longer OS than patients who did not receive surgery (70.1 months vs 23.9 months; p = 0.017, n = 11). Among 47 patients with stage IV carcinoma, 12 patients who received an extended thymothymectomy had a longer PFS than 35 patients who did not receive surgery (18.9 months vs 8.7 months; p = 0.029). Among 30 patients (with stage I- IV carcinoma) who received primary lesion surgery, 19 patients received an R0 resection and 9 patients of the 19 patients received adjuvant radiotherapy. These patients had longer PFS (50.3 months) than 2 patients who received adjuvant chemotherapy (5.9 months) or 4 patients who received concurrent chemoradiotherapy (7.5 months) after surgery (p = 0.003).

Conclusions: Surgical resection should be considered for patients with thymic carcinoma, even for patients with locally advanced or stage IV carcinoma. Adjuvant radiotherapy resulted in a better PFS after R0 resection.

Citing Articles

American Radium Society Appropriate Use Criteria for Radiation Therapy in the Multidisciplinary Management of Thymic Carcinoma.

Chun S, Rimner A, Amini A, Chang J, Donington J, Edelman M JAMA Oncol. 2023; 9(7):971-980.

PMID: 37186595 PMC: 11665036. DOI: 10.1001/jamaoncol.2023.1175.

A single-center experience: management of patients with thymic epithelial tumors.

Kemper M, Moradzadeh M, Bellon E, Bahar A, Groteluschen R, Reeh M World J Surg Oncol. 2020; 18(1):202.

PMID: 32791986 PMC: 7427055. DOI: 10.1186/s12957-020-01988-4.

A new application for argon beam coagulation: the thymoma patient with pleural recurrence.

Tseng Y, Tseng Y, Tang E, Goan Y J Thorac Dis. 2018; 10(5):E355-E358.

PMID: 29997993 PMC: 6006104. DOI: 10.21037/jtd.2018.04.114.

Chemoradiotherapy for unresectable cases of thymic epithelial tumors: a retrospective study.

Kashima J, Okuma Y, Murata H, Watanabe K, Hosomi Y, Hishima T J Thorac Dis. 2017; 9(10):3911-3918.

PMID: 29268401 PMC: 5723825. DOI: 10.21037/jtd.2017.08.133.

References

Venuta F, Rendina E, Longo F, De Giacomo T, Anile M, Mercadante E . Long-term outcome after multimodality treatment for stage III thymic tumors. Ann Thorac Surg. 2003; 76(6):1866-72. DOI: 10.1016/s0003-4975(03)01020-8. View

Agatsuma T, Koizumi T, Kanda S, Ito M, Urushihata K, Yamamoto H . Combination chemotherapy with doxorubicin, vincristine, cyclophosphamide, and platinum compounds for advanced thymic carcinoma. J Thorac Oncol. 2011; 6(12):2130-4. DOI: 10.1097/JTO.0b013e31822e71c0. View

Ettinger D, Riely G, Akerley W, Borghaei H, Chang A, Cheney R . Thymomas and thymic carcinomas: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2013; 11(5):562-76. DOI: 10.6004/jnccn.2013.0072. View

Hirai F, Yamanaka T, Taguchi K, Daga H, Ono A, Tanaka K . A multicenter phase II study of carboplatin and paclitaxel for advanced thymic carcinoma: WJOG4207L. Ann Oncol. 2014; 26(2):363-8. DOI: 10.1093/annonc/mdu541. View

Sakai M, Onuki T, Inagaki M, Yamaoka M, Kitazawa S, Kobayashi K . Early-stage thymic carcinoma: is adjuvant therapy required?. J Thorac Dis. 2013; 5(2):161-4. PMC: 3621945. DOI: 10.3978/j.issn.2072-1439.2013.01.06. View

Ettinger D, Wood D, Akerley W, Bazhenova L, Borghaei H, Camidge D . Non-small cell lung cancer, version 1.2015. J Natl Compr Canc Netw. 2014; 12(12):1738-61. DOI: 10.6004/jnccn.2014.0176. View

Yano M, Sasaki H, Yokoyama T, Yukiue H, Kawano O, Suzuki S . Thymic carcinoma: 30 cases at a single institution. J Thorac Oncol. 2008; 3(3):265-9. DOI: 10.1097/JTO.0b013e3181653c71. View

Song Z, Zhang Y . Outcomes after surgical resection of thymic carcinoma: A study from a single tertiary referral centre. Eur J Surg Oncol. 2014; 40(11):1523-7. DOI: 10.1016/j.ejso.2014.05.011. View

Liu H, Hsu W, Chen Y, Chan Y, Wu Y, Huang M . Primary thymic carcinoma. Ann Thorac Surg. 2002; 73(4):1076-81. DOI: 10.1016/s0003-4975(01)03607-4. View

10.

Okereke I, Kesler K, Freeman R, Rieger K, Birdas T, Ascioti A . Thymic carcinoma: outcomes after surgical resection. Ann Thorac Surg. 2012; 93(5):1668-72. DOI: 10.1016/j.athoracsur.2012.01.014. View

11.

de Jong W, Blaauwgeers J, Schaapveld M, Timens W, Klinkenberg T, Groen H . Thymic epithelial tumours: a population-based study of the incidence, diagnostic procedures and therapy. Eur J Cancer. 2007; 44(1):123-30. DOI: 10.1016/j.ejca.2007.11.004. View

12.

Venuta F, Rendina E, Anile M, De Giacomo T, Vitolo D, Coloni G . Thymoma and thymic carcinoma. Gen Thorac Cardiovasc Surg. 2012; 60(1):1-12. DOI: 10.1007/s11748-011-0814-0. View

13.

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

14.

Inoue A, Sugawara S, Harada M, Kobayashi K, Kozuki T, Kuyama S . Phase II study of Amrubicin combined with carboplatin for thymic carcinoma and invasive thymoma: North Japan Lung Cancer group study 0803. J Thorac Oncol. 2014; 9(12):1805-9. DOI: 10.1097/JTO.0000000000000362. View

15.

Ahmad U, Yao X, Detterbeck F, Huang J, Antonicelli A, Filosso P . Thymic carcinoma outcomes and prognosis: results of an international analysis. J Thorac Cardiovasc Surg. 2014; 149(1):95-100, 101.e1-2. DOI: 10.1016/j.jtcvs.2014.09.124. View

16.

Okuma Y, Saito M, Hosomi Y, Sakuyama T, Okamura T . Key components of chemotherapy for thymic malignancies: a systematic review and pooled analysis for anthracycline-, carboplatin- or cisplatin-based chemotherapy. J Cancer Res Clin Oncol. 2014; 141(2):323-31. PMC: 4293490. DOI: 10.1007/s00432-014-1800-6. View

17.

Weksler B, Dhupar R, Parikh V, Nason K, Pennathur A, Ferson P . Thymic carcinoma: a multivariate analysis of factors predictive of survival in 290 patients. Ann Thorac Surg. 2012; 95(1):299-303. DOI: 10.1016/j.athoracsur.2012.09.006. View

18.

Kawasaki H, Taira N, Ichi T, Yohena T, Kawabata T, Ishikawa K . Weekly chemotherapy with cisplatin, vincristine, doxorubicin, and etoposide followed by surgery for thymic carcinoma. Eur J Surg Oncol. 2014; 40(9):1151-5. DOI: 10.1016/j.ejso.2014.03.006. View